Regarding oncogene-addicted NSCLC, two studies focusing on EGFR-mutant cohorts found sarcopenia defined as per Fearon et al. prognostic, with sarcopenia ranging between 54–60.6% [23,36]. The gene discussed is EGFR; the disease is sarcopenia.